PL448268A1 - Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor - Google Patents

Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor

Info

Publication number
PL448268A1
PL448268A1 PL448268A PL44826824A PL448268A1 PL 448268 A1 PL448268 A1 PL 448268A1 PL 448268 A PL448268 A PL 448268A PL 44826824 A PL44826824 A PL 44826824A PL 448268 A1 PL448268 A1 PL 448268A1
Authority
PL
Poland
Prior art keywords
compound
brain tumor
diagnosing
enzymatic activity
diagnostic marker
Prior art date
Application number
PL448268A
Other languages
Polish (pl)
Inventor
Adam LESNER
Natalia Gruba
Original Assignee
Urteste Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urteste Spółka Akcyjna filed Critical Urteste Spółka Akcyjna
Priority to PL448268A priority Critical patent/PL448268A1/en
Priority to PCT/PL2025/050034 priority patent/WO2025216642A1/en
Publication of PL448268A1 publication Critical patent/PL448268A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest nowy związek chemiczny - marker diagnostyczny — do zastosowania medycznego, dokładniej w diagnostyce nowotworowej, w szczególności w diagnostyce guza mózgu. Przedmiotem zgłoszenia jest także sposób in vitro wykrywania aktywności enzymatycznej obecnej w płynie ustrojowym osobnika, w szczególności pochodzącej z komórek guza mózgu, z użyciem takiego związku. Przedmiotem zgłoszenia jest ponadto sposób in vitro diagnozowania guza mózgu, z użyciem takiego związku, zestaw zawierający taki związek oraz zastosowanie takiego związku do wykrywania aktywności enzymatycznej swoistej dla guza mózgu i zastosowanie takiego związku do diagnozowania guza mózgu. Przedmiotem zgłoszenia jest także taki związek do zastosowania jako marker diagnostyczny guza mózgu oraz sposób leczenia guza mózgu obejmujący etap przeprowadzania sposobu diagnozowania guza mózgu jak określono powyżej z zastosowaniem takiego związku.The subject of the application is a new chemical compound—a diagnostic marker—for medical use, specifically in cancer diagnostics, particularly in brain tumor diagnosis. The subject of the application is also an in vitro method for detecting enzymatic activity present in a subject's body fluid, particularly derived from brain tumor cells, using such a compound. The subject of the application is also an in vitro method for diagnosing a brain tumor using such a compound, a kit containing such a compound, and the use of such a compound for detecting enzymatic activity specific to a brain tumor, and the use of such a compound for diagnosing a brain tumor. The subject of the application is also such a compound for use as a diagnostic marker for a brain tumor, and a method for treating a brain tumor, comprising the step of performing a method for diagnosing a brain tumor as defined above using such a compound.

PL448268A 2024-04-11 2024-04-11 Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor PL448268A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL448268A PL448268A1 (en) 2024-04-11 2024-04-11 Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor
PCT/PL2025/050034 WO2025216642A1 (en) 2024-04-11 2025-04-10 Enzymatic activity based method and marker for the diagnosis of brain tumour

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448268A PL448268A1 (en) 2024-04-11 2024-04-11 Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor

Publications (1)

Publication Number Publication Date
PL448268A1 true PL448268A1 (en) 2025-10-13

Family

ID=95941890

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448268A PL448268A1 (en) 2024-04-11 2024-04-11 Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor

Country Status (2)

Country Link
PL (1) PL448268A1 (en)
WO (1) WO2025216642A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039963A1 (en) * 2005-09-30 2007-04-12 Niigata University Brain tumor marker for prediction of prognosis of patient with brain tumor and use thereof
WO2018004240A1 (en) * 2016-06-27 2018-01-04 주식회사 옵티팜 Use of nupr1 in diagnosis and treatment of brain tumor
KR20220147530A (en) * 2021-04-27 2022-11-03 고려대학교 산학협력단 Biomarker composition for diagnosis of brain tumor comprising Tetraspanin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187629A1 (en) * 2017-04-07 2018-10-11 Avelas Biosciences, Inc. Ratiometric fluorescence imaging methods
PL244818B1 (en) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia A liver cancer diagnostic marker compound, a method for detecting enzymatic activity, a method for diagnosing liver cancer, a kit containing such a compound and a compound for medical use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039963A1 (en) * 2005-09-30 2007-04-12 Niigata University Brain tumor marker for prediction of prognosis of patient with brain tumor and use thereof
WO2018004240A1 (en) * 2016-06-27 2018-01-04 주식회사 옵티팜 Use of nupr1 in diagnosis and treatment of brain tumor
KR20220147530A (en) * 2021-04-27 2022-11-03 고려대학교 산학협력단 Biomarker composition for diagnosis of brain tumor comprising Tetraspanin-12

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SMITH, E.R. ET AL.: "Clin Cancer Res. 2008 Apr 15; 14(8): 2378-86", URINARY BIOMARKERS PREDICT BRAIN TUMOR PRESENCE AND RESPONSE TO THERAPY. *
WU, J. ET AL.: "Chin Neurosurg Jl 2020; 6:11", URINARY BIOMARKER DISCOVERY IN GLIOMAS USING MASS SPECTROMETRY-BASED CLINICAL PROTEOMICS. *

Also Published As

Publication number Publication date
WO2025216642A1 (en) 2025-10-16
WO2025216642A4 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
Nordsmark et al. Measurement of human tumour oxygenation status by a polarographic needle electrode: an analysis of inter-and intratumour heterogeneity
US4407300A (en) Potentiometric diagnosis of cancer in vivo
Dean et al. Do psychological factors predict survival in breast cancer?
van Loenen et al. Group changes in cognitive performance after surgery mask changes in individual patients with glioblastoma
PL448268A1 (en) Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor
ABRAMSON et al. Skin reactions: XII. Patterns produced in the skin by electrophoresis of dyes
PL445390A1 (en) Compound, diagnostic marker for breast cancer, method of detecting enzymatic activity, method of diagnosing breast cancer, kit comprising such a compound and uses of such a compound and method of treating breast cancer
PL439405A1 (en) Compound - a diagnostic marker for liver cancer, method for detecting enzyme activity, method for diagnosing liver cancer, kit comprising such a compound and uses of such a compound and method for treating liver cancer
Li et al. Effective strategies to enhance the diagnosis and treatment of RCC: the application of biocompatible materials
Li et al. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: a prospective analysis
Neuberger et al. Biosynthesis of porphyrins and congenital porphyria
PL439760A1 (en) Compound - a diagnostic marker for lung cancer, method for diagnosing lung cancer, a kit comprising such a compound and applications of such a compound and lung cancer treating method
PL443839A1 (en) Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer
PL441568A1 (en) Compound - a diagnostic marker for endometrial cancer, method for detecting enzymatic activity, method for diagnosing endometrial cancer, kit containing such a compound, and uses of such a compound and method for treating endometrial cancer
PL440782A1 (en) Compound - a diagnostic marker for bowel cancer, a method for detecting enzymatic activity, method for diagnosing intestinal cancer, a kit containing such a compound, and uses of such a compound and a method for treating intestinal cancer
PL440976A1 (en) A kidney cancer diagnostic marker compound, a method for detecting enzyme activity, a method for diagnosing kidney cancer, a kit containing such a compound, and uses of such a compound and a method for treating kidney cancer
Peirson et al. Biopsy of the prostate with the Silverman needle
PL443432A1 (en) Compound - diagnostic marker for biliary tract cancer, method of detecting enzymatic activity, method of diagnosing biliary tract cancer, kit containing such a compound and uses of such a compound and method of treating biliary tract cancer
MX2025003506A (en) Compound - diagnostic marker for ovarian cancer, method for detecting enzymatic activity, method for diagnosis of ovarian cancer, kit comprising the compound, uses of the compound and method for the treatment of ovarian cancer
Neumeister et al. Advances in hypoxyradiotherapy
CN109846903A (en) A set of medicines combined with pulmonary lavage for the treatment of pulmonary fibrosis
RU2680085C1 (en) Method of differential diagnostics of skin scar type in women
de Takats et al. Sterility of the Male after Sympathectomies
Babkina et al. Parameters of the oxidative-reduction system of the homeostasis in female transplant patients with tumors of the reproductive system treated with hyperbaric oxygen therapy
Scherlag The development of the His bundle recording technique.